(News Bulletin 247) – Carmat today announces the launch of a fundraising campaign of around 30 million euros via the issue of new shares at a fixed price of 10.50 euros per share aimed at specialized and strategic investors as well as retail investors.
The company plans to use the proceeds of the Fundraising to support the development of its activities and in particular, the ramp-up of its production, the recovery and growth of Aeson sales and the launch of the Eficas clinical study. in France.
“This new funding comes at a crucial time for Carmat as we prepare for a first full year of sales in the Company’s history,” commented Stéphane Piat, CEO of the company.
‘The renewed support of several of our reference shareholders and other investors will allow us in particular to gradually replenish our stock of implantable prostheses, to soon initiate the Eficas clinical study in France, and above all to develop our sales in Europe’, concludes the manager.
Copyright (c) 2022 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.